Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer that has not spread to other parts of the body (stage M0).
- Your cancer is either triple-negative or has very low levels of hormone receptors (HR-low+) and is HER2-negative, and your doctor plans to treat it like triple-negative breast cancer.
- You have not received any previous treatment (such as surgery, radiation, or chemotherapy) for this breast cancer diagnosis.
- You have not had prior treatment with a type of drug called a checkpoint inhibitor (like Keytruda) or with an antibody targeting HER3 or a drug similar to Enhertu.
- You do not have uncontrolled heart or lung conditions, active infections, or a history of interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
This trial tests a new drug, patritumab deruxtecan, combined with other anti-cancer drugs for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if these combinations can shrink tumors or slow cancer growth.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.